Histaminergic Basis of Fatigue in Multiple Sclerosis
NCT04764383 is a phase 2 interventional trial sponsored by University of Miami. As of 21 Nov 2026, it was withdrawn. It studies Histidine, Lodosyn and Placebo in Multiple Sclerosis. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 1 Jan 2022 and a primary completion date of 30 Oct 2022.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04764383 |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | University of Miami |
| Enrollment | 0 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Multiple Sclerosis |
| Drugs | Histidine, Lodosyn and Placebo |
| Start | 1 Jan 2022 |
| Primary completion | 30 Oct 2022 |
| Study completion | 30 Oct 2022 |
| Last update posted | 29 Jul 2021 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Kottil Rammohan, MD
University of Miami
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Miami
Miami
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04764383
Each answer restates registry values shown on this page.
What is NCT04764383?
NCT04764383 is a phase 2 interventional trial sponsored by University of Miami. It studies Histidine, Lodosyn and Placebo in Multiple Sclerosis.
Who leads NCT04764383?
The registry names Kottil Rammohan, MD (principal investigator, University of Miami) as the overall official.
Where does NCT04764383 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04764383 study?
The registered drug and biological interventions are Histidine, Lodosyn and Placebo.
When did NCT04764383 end?
The registry lists a primary completion date of 30 Oct 2022 and a study completion date of 30 Oct 2022. The sponsor last updated the record on 29 Jul 2021.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.